Topic: drug sales

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.

With two oncology blockbuster already facing U.S. biosims, Roche is facing a tough road ahead. Now, a third Roche cancer med is in the firing line.

Hey, AbbVie: Botox may be a long-term winner, but not every drug in Allergan's stable is shining quite so brightly. 

AbbVie is riding high on the launch of RA blockbuster-to-be Rinvoq and a looming merger with Allergan. Could competition for Imbruvica be a buzzkill?

Bristol-Myers' Eliquis is keeping up with its world-beater rep, but analysts worry about I-O med Opdivo—and execs say the med faces a tough 2020.

Thanks to a market-share grab for triple-drug COPD therapy Trelegy Ellipta, GSK's respiratory strategy is working as planned.

Lilly is facing off against new competition and dealing with lower pricing in the U.S., but key drug classes are continuing to expand, its CEO said.

Alexion is pushing hard to get patients on its blockbuster Soliris over to a follow-up drug, but the older med's sales are still hanging in there.

JPMorgan discovered concerns about the efficacy of Novartis' Zolgensma that could make it difficult for the SMA gene therapy to meet expectations.